Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
PLoS One ; 12(3): e0174233, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28346490

RESUMO

BACKGROUND: Human immunodeficiency virus (HIV) and malaria co-infection may present worse health outcomes in the tropics. Information on HIV/malaria co-infection effect on immune-hematological profiles is critical for patient care and there is a paucity of such data in Nigeria. OBJECTIVE: To evaluate immune-hematological profiles among HIV infected patients compared to HIV/malaria co-infected for ART management improvement. METHODS: This was a cross sectional study conducted at Infectious Disease Hospital, Kano. A total of 761 consenting adults attending ART clinic were randomly selected and recruited between June and December 2015. Participants' characteristics and clinical details including two previous CD4 counts were collected. Venous blood sample (4ml) was collected in EDTA tube for malaria parasite diagnosis by rapid test and confirmed with microscopy. Hematological profiles were analyzed by Sysmex XP-300 and CD4 count by Cyflow cytometry. Data was analyzed with SPSS 22.0 using Chi-Square test for association between HIV/malaria parasites co-infection with age groups, gender, ART, cotrimoxazole and usage of treated bed nets. Mean hematological profiles by HIV/malaria co-infection and HIV only were compared using independent t-test and mean CD4 count tested by mixed design repeated measures ANOVA. Statistical significant difference at probability of <0.05 was considered for all variables. RESULTS: Of the 761 HIV infected, 64% were females, with a mean age of ± (SD) 37.30 (10.4) years. Prevalence of HIV/malaria co-infection was 27.7% with Plasmodium falciparum specie accounting for 99.1%. No statistical significant difference was observed between HIV/malaria co-infection in association to age (p = 0.498) and gender (p = 0.789). A significantly (p = 0.026) higher prevalence (35.2%) of co-infection was observed among non-ART patients compared to (26%) ART patients. Prevalence of co-infection was significantly lower (20.0%) among cotrimoxazole users compared to those not on cotrimoxazole (37%). The same significantly lower co-infection prevalence (22.5%) was observed among treated bed net users compared to those not using treated bed nets (42.9%) (p = 0.001). Out of 16 hematology profiles evaluated, six showed significant difference between the two groups (i) packed cell volume (p = <0.001), (ii) mean cell volume (p = 0.005), (iii) mean cell hemoglobin concentration (p = 0.011), (iv) absolute lymphocyte count (p = 0.022), (v) neutrophil percentage count (p = 0.020) and (vi) platelets distribution width (p = <0.001). Current mean CD4 count cell/µl (349±12) was significantly higher in HIV infected only compared to co-infected (306±17), (p = 0.035). A significantly lower mean CD4 count (234.6 ± 6.9) was observed among respondents on ART compared to non-ART (372.5 ± 13.2), p<0.001, mean difference = -137.9). CONCLUSION: The study revealed a high burden of HIV and malaria co-infection among the studied population. Co-infection was significantly lower among patients who use treated bed nets as well as cotrimoxazole chemotherapy and ART. Six hematological indices differed significantly between the two groups. Malaria and HIV co-infection significantly reduces CD4 count. In general, to achieve better management of all HIV patients in this setting, diagnosing malaria, prompt antiretroviral therapy, monitoring CD4 and some hematology indices on regular basis is critical.


Assuntos
Antirretrovirais/uso terapêutico , Coinfecção/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Malária/tratamento farmacológico , Adulto , Antimaláricos/uso terapêutico , Contagem de Linfócito CD4 , Coinfecção/sangue , Coinfecção/epidemiologia , Estudos Transversais , Feminino , HIV/efeitos dos fármacos , Infecções por HIV/sangue , Infecções por HIV/epidemiologia , Humanos , Malária/sangue , Malária/epidemiologia , Masculino , Pessoa de Meia-Idade , Nigéria/epidemiologia , Plasmodium/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Prevalência , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
2.
Biol Trace Elem Res ; 168(2): 335-9, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26043914

RESUMO

Proper trace element level is crucial for the organs in maintaining normal physiological functions. Multiple organ failure (MOF) might be added to critically ill patients due to a lack of trace elements. Alterations of trace element levels in brain, heart, liver, and kidney after severe trauma, however, have been little studied so far. In this study, tissue samples of the frontal cortex of the brain, interventricular septum of the heart, right lobe of the liver, and upper pole of the kidney were obtained from forensic autopsies, of which 120 cases died during the 5th to 15th day of hospitalization, whereas the trauma death group and 43 cases immediately died due to severe craniocerebral trauma as the control group. Copper (Cu), iron (Fe), zinc (Zn), and selenium (Se) were quantified by inductively coupled plasma atomic emission spectrophotometry (ICP-AES). Cu, Fe, Zn, and Se concentrations in the brain, heart, liver, and kidney in the trauma group decreased dramatically (p<0.05) compared to the control group. The incidence of secondary infection and multiple organ failure (MOF) in the trauma death group were 78.33 and 29.17%, respectively. The concentrations of all elements exhibited a significant correlation with secondary infection and MOF (p<0.01). Our data suggest that low concentrations of Cu, Fe, Zn, and Se in pivotal organs may contribute to the incidence of secondary infection and MOF after severe trauma, which to some extent results in death.


Assuntos
Coinfecção/sangue , Insuficiência de Múltiplos Órgãos/sangue , Oligoelementos/análise , Ferimentos e Lesões/sangue , Adulto , Autopsia , Encéfalo/metabolismo , Coinfecção/mortalidade , Cobre/análise , Feminino , Hospitalização , Humanos , Ferro/análise , Rim/metabolismo , Fígado/metabolismo , Masculino , Pessoa de Meia-Idade , Insuficiência de Múltiplos Órgãos/mortalidade , Miocárdio/metabolismo , Selênio/análise , Espectrofotometria Atômica , Distribuição Tecidual , Ferimentos e Lesões/mortalidade , Zinco/análise
3.
Carbohydr Polym ; 109: 71-6, 2014 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-24815403

RESUMO

Chicks' co-infection with immunosuppressive virus and bacteria seriously threaten the development of the poultry industry. In this study, a model was established in which chicks were injected with either subgroup B ALV (ALV-B)+Bordetella avium (B. avium), or ALV-B+B. avium+Taishan Pinus massoniana pollen polysaccharide (TPPPS), or B. avium only, or B. avium+TPPPS. The data showed that the group injected with ALV-B and B. avium exhibited significant inhibition of the immune function and therefore increased pathogenicity compared with the group injected with B. avium-only. Application of TPPPS effectively alleviated immunosuppression, and body weights increased sharply in the TPPPS groups compared with non-TPPPS groups. To some extent, TPPPS may reduce the proliferation of ALV-B. These results suggest that Pinus pollen polysaccharides are beneficial treating co-infections with immunosuppressive virus and bacteria and therefore have potential for development into safe and effective immunoregulator.


Assuntos
Leucose Aviária/tratamento farmacológico , Infecções por Bordetella/veterinária , Galinhas/imunologia , Coinfecção/veterinária , Fatores Imunológicos/administração & dosagem , Extratos Vegetais/administração & dosagem , Polissacarídeos/administração & dosagem , Animais , Leucose Aviária/sangue , Leucose Aviária/imunologia , Vírus da Leucose Aviária/imunologia , Proteínas Aviárias/sangue , Infecções por Bordetella/sangue , Infecções por Bordetella/tratamento farmacológico , Infecções por Bordetella/imunologia , Bordetella avium/imunologia , Galinhas/microbiologia , Galinhas/virologia , Coinfecção/sangue , Coinfecção/tratamento farmacológico , Coinfecção/imunologia , Interferon gama/sangue , Interleucina-2/sangue , Pinus/química , Pólen/química , Linfócitos T/imunologia
4.
Int J Infect Dis ; 17(10): e907-12, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23816410

RESUMO

OBJECTIVES: To describe HIV RNA levels during tuberculosis (TB) infection in patients co-infected with TB and HIV. Moreover, to examine the p24 antigen profile during TB treatment. METHODS: We examined the changes in CD4 cell count, HIV RNA, and p24 levels during anti-tuberculous therapy in a group of TB/HIV-1 co-infected and HIV-untreated patients from Guinea-Bissau. RESULTS: A total of 365 TB patients were enrolled, of whom 76 were co-infected with HIV-1 and 19 were dually infected with HIV-1 + HIV-2. No significant changes in CD4, HIV RNA, or p24 levels were found during 8 months of TB treatment. HIV RNA levels correlated well with p24 (Spearman's R(2)=0.52, p<0.00001) and both markers were strong predictors of mortality. Initial HIV RNA levels correlated with a clinical TB severity index--the TBscore (Spearman's R(2)=0.23, p=0.02)--and the TBscore decreased dramatically during TB treatment although HIV RNA levels remained unchanged. CONCLUSION: We found no significant changes in CD4, HIV RNA, or p24 antigen levels during 8 months of TB treatment among TB/HIV co-infected individuals, who did not receive antiretroviral treatment. The markers were unaffected by a strong improvement in TBscore and all three markers showed predictive capacity for mortality risk.


Assuntos
Antituberculosos/farmacologia , Coinfecção/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , HIV-2/imunologia , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Antituberculosos/uso terapêutico , Biomarcadores/sangue , Contagem de Linfócito CD4 , Coinfecção/sangue , Coinfecção/mortalidade , Suplementos Nutricionais , Quimioterapia Combinada , Etambutol/farmacologia , Etambutol/uso terapêutico , Feminino , Guiné-Bissau , Proteína do Núcleo p24 do HIV/sangue , Infecções por HIV/sangue , Infecções por HIV/mortalidade , Humanos , Isoniazida/farmacologia , Isoniazida/uso terapêutico , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Pirazinamida/farmacologia , Pirazinamida/uso terapêutico , RNA Viral , Rifampina/farmacologia , Rifampina/uso terapêutico , Tuberculose Pulmonar/sangue , Tuberculose Pulmonar/imunologia , Tuberculose Pulmonar/mortalidade , Vitamina D/administração & dosagem , Adulto Jovem
5.
Swiss Med Wkly ; 142: w13323, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22252925

RESUMO

BACKGROUND AND AIMS: A better understanding of the relationship of homocysteine with cardiovascular risk factors is needed. The objectives of this study were to assess the serum level of homocysteine in HIV-infected patients and to analyse the possible association of increased levels of the amino acid with cardiovascular risk factors, demographic and clinical characteristics of participants. METHODS: Cross-sectional study carried out as a supplementary task to the usual controls necessary in HIV-infected patients in the outpatient clinic of the Hospital General of Castellon, Spain. For two consecutive visits the demographic, clinical and HIV-related characteristics and blood analyses results were obtained for each participant. Homocysteine serum level was documented and the possible association of the amino acid with all the other study variables was assessed with a multiple linear regression analysis. RESULTS: A total of 145 patients were included. The mean homocysteine serum level of all participants was 11.9 ± 5.9 µmol/L. A total of 54 patients (37%) presented homocysteine serum levels higher than the upper limit of normal. An association was found between higher homocysteine serum level and the following variables: family history of early coronary disease (P = 0.027), sexual HIV risk behaviour (P = 0.016), hepatitis C virus co-infection (P = 0.002), higher height (P = 0.002), higher diastolic blood pressure (P = 0.049), lower serum level of folic acid (P <0.001), and lower serum level of vitamin B12 (P = <0.001). CONCLUSION: In the HIV population, increased homocysteine serum level is associated with sexual risk behaviour and hepatitis C virus coinfection.


Assuntos
Doenças Cardiovasculares/sangue , Infecções por HIV/sangue , Hepacivirus , Hepatite C/complicações , Homocisteína/sangue , Comportamento Sexual , Adulto , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Coinfecção/sangue , Estudos Transversais , Feminino , Ácido Fólico/sangue , HIV , Infecções por HIV/complicações , Hepatite C/sangue , Humanos , Masculino , Fatores de Risco , Assunção de Riscos , Vitamina B 12/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA